Crohn s disease (CD) is a chronic disease most commonly
|
|
- Duane Anderson
- 5 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Prediction of Need for Surgery After Endoscopic Balloon Dilation of Ileocolic Anastomotic Stricture in Patients With Crohn s Disease Lei Lian, M.D., Ph.D. 1,2 Luca Stocchi, M.D. 1 Bo Shen, M.D. 2 Xiaobo Liu, M.S. 3 Jessica Ma 2 Brook Zhang 2 Feza Remzi, M.D. 1 1 Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio 2 Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio 3 Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio BACKGROUND: Endoscopic balloon dilation is used to treat ileocolic anastomotic stricture attributed to recurrent Crohn s disease. OBJECTIVE: The purpose of this work was to investigate long-term outcomes after dilation of ileocolic anastomotic stricture and to identify risk factors associated with the need for subsequent surgical intervention. DESIGN: This was a retrospective study based on chart review of an electronic medical chart system. SETTINGS: The study was conducted at a tertiary care center. PATIENTS: All of the eligible patients with ileocolic anastomotic stricture attributed to recurrent Crohn s disease treated with endoscopic dilation between December 1998 and May 2013 were evaluated. Patients with concurrent enterocutaneous fistula or abdominal or pelvic abscess were excluded. MAIN OUTCOME MEASURES: The main outcome measure was the need for subsequent salvage surgery because of stricture-related symptoms. Funding/Support: Dr Stocchi was partially supported by the Story Garschina Endowed Chair. Financial Disclosure: None reported. Podium presentation at the meeting of The American Society of Colon and Rectal Surgeons, Hollywood, FL, May 17 to 21, Correspondence: Luca Stocchi, M.D., Desk A 30, Department of Colorectal Surgery, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH stocchl@ccf.org Dis Colon Rectum 2015; 58: DOI: /DCR The ASCRS 2015 Diseases of the Colon & Rectum Volume 58: 4 (2015) RESULTS: A total of 185 patients with Crohn s disease (45.9% women; mean age, 43.1 years; symptomatic strictures in 80%) underwent 462 endoscopic dilations of ileocolic anastomosis (median per-patient dilations, 2; range, 1 3). During a mean follow-up of 3.9 years, 27 patients (14.6%) required hospitalization without surgery for stricture-related symptoms, and 66 patients (35.7%) required subsequent salvage surgery. Specific medical management, type of anastomosis, and endoscopic intralesional steroid injection had no impact on the risk of needing surgery. Significant factors associated with the need for surgery on multivariable analysis were symptomatic disease (HR, 3.54 [95% CI, ]), longer time interval from last surgery (HR, 1.05 [95% CI, ]), and radiographic proximal bowel dilation (HR, 2.36 [95% CI, ]). A nomogram estimating the need for surgery was created with a concordance index of LIMITATIONS: The study was limited by its retrospective design. CONCLUSIONS: Although endoscopic dilation is a valid option for ileocolic anastomotic stricture attributed to recurrent Crohn s disease, the need for surgery is common. The nomogram can identify patients who might benefit from upfront surgery. KEY WORDS: Anastomotic stricture; Crohn s disease; Endoscopic balloon dilation; Nomogram; Prediction. Crohn s disease (CD) is a chronic disease most commonly affecting the terminal ileum. It is estimated that 80% of patients with CD require surgical treatment at some point, 1 most commonly ileocolic resection to treat CD-related strictures. 2 However, the recurrence rate is high after ileocolic resection and may occur 423
2 424 Lian et al: Crohn s Anastomotic Stricture Dilation at the anastomotic site or in the neoterminal ileum. 3,4 The cumulative probability of clinical recurrence is estimated at 10% per year. 5 As recurrent disease progresses, anastomotic stricture may ensue and lead to bowel obstruction. The benefit of medical therapy in this setting is limited 6 because of the mechanical nature of stricture, and surgical resection with reanastomosis is often required. Consequently, one fourth of the patients will require a second operation by 4 years, and approximately one-half by 10 to 15 years. 7 9 Endoscopic through-the-scope balloon dilation (EBD) of the strictures has emerged as an effective alternative in patients with CD stricture, 10 particularly for short and isolated strictures at the ileocolic anastomosis (ICA), which are often linear 11 and may appear in the complete absence of disease recurrence. 12 Although anastomotic strictures can be more technically challenging than de novo strictures, 13 anastomotic strictures may also be associated with improved long-term outcomes when compared with de novo strictures. 14 Currently, the majority of studies summarizing the outcomes of EBD of CD strictures have either a relatively small sample size with short follow-up or include both primary and secondary (anastomotic) strictures. 10 Few studies have specifically focused on ICA. 15 In addition, data pertaining to factors associated with long-term success as defined by the need for subsequent surgical resection after EBD for ICA stricture in patients with CD remain sparse. 10,16 18 The aims of this study were, therefore, to analyze long-term outcomes after EBD for ICA stricture in patients with CD in a single institution and to identify variables observable at initial EBD that were risk factors for subsequent salvage surgery to treat ICA stricture attributed to recurrent CD. PATIENTS AND METHODS Patients The study was approved by the institutional review board at the Cleveland Clinic. A historical cohort of eligible patients with ICA stricture treated with EBD between December 1998 and May 2013 were evaluated. Inclusion Criteria and Exclusion Criteria Patients were identified from an electronic health record (EHR; Epicsys, Verona, WI). Inclusion criteria for the study were patients seen in our IBD center and having a diagnosis of CD (International Classification of Diseases, Ninth Revision, Clinical Modification, code 555.9) documented on EHR and EBD in our billing database. This information was then confirmed by reviewing electronic charts. Clinical notes and endoscopy reports were reviewed to confirm EBD of ICA and to exclude patients with dilation of primary stricture. Patients with ileorectal anastomosis were excluded. Demographic and Clinical Variables Demographics (age, sex, and race) were extracted from the EHR. Clinical, endoscopic, histologic, and radiographic data were collected by chart review. Collected data included age at diagnosis, age at the time of treatment, duration of CD (time interval between diagnosis of CD and EBD of ICA stricture), symptoms, smoking history (never, current, or ex-smoker), presence of extraintestinal manifestations, and date of most-recent follow-up. CD medications within the 3 months before EBD were categorized into 5-aminosalicylates, immunomodulators, steroids (oral or intravenous corticosteroids), or biologics. Escalation of medical therapy was defined as use of increased dosage of the same drug or use of a higher class of CD medication after EBD as compared with that before EBD. Endoscopy reports were reviewed to extract data on stricture length, presence and location of concurrent stricture, balloon size, use of intralesional steroid injection, and immediate complications (major bleeding, perforation, or death). Imaging reports within the 3 months preceding EBD (CT, CT enterography, magnetic resonance enterography, or barium studies) were reviewed to determine stricture length and the presence of proximal bowel dilation. Concurrent stricture was defined as the presence of additional stricture(s) other than the ICA stricture located elsewhere in the ileum, jejunum, or colon. Indications and Technique of Endoscopic Balloon Dilation The decision to perform EBD generally followed the diagnosis of ICA stricture based on clinical presentation and imaging studies. However, EBD could also be performed on ICA strictures that were incidentally encountered in the course of a routine surveillance colonoscopy at the discretion of the endoscopist. Anastomotic or preanastomotic strictures >4 cm and known fistulizing abdominal CD were considered to be not amenable to EBD or as contraindications to EBD in our practice. The procedure was typically done by IBD specialists or therapeutic endoscopists at our institution. Once the stricture was endoscopically visualized, the through-the-scope controlled radial expansion dilating balloon was passed through the biopsy channel through the stricture. The balloon diameter ranged between 12 and 20 mm. Once in place, the balloon was inflated with water using a stepwise approach. The pressure was monitored closely by the assistant throughout the procedure. The pressure was maintained for a few seconds, and then the balloon was deflated. The process could be repeated several times during the same procedure until an adequate visualization of the lumen was achieved unless an angulation or narrow stricture prohibited the passage of the colonoscope. Specific balloon size and endoscopic dilation technique were left at the discretion of the individual endoscopist.
3 Diseases of the Colon & Rectum Volume 58: 4 (2015) 425 Outcome Measurements Primary outcome was the need for salvage surgery to treat the ICA stricture because of recurrent CD. Other outcomes, including immediate technical failure, repeated dilation, stricture-associated emergency department visit, hospitalization, and escalation of medical therapy to immunomodulators/biologics were also examined. Major complications were defined as perforation, excessive bleeding requiring transfusion, and death. Technical failure was defined as an inability to pass the endoscope through the anastomosis after dilation. Patient follow-up started from the date of the first EBD until the date of the primary outcome or censoring at the date of the most recent contact. Patients and/or treating physicians were contacted via telephone if no follow-up data were retrievable from our medical charts. Statistical Analysis Descriptive statistics included means and SDs or medians and interquartile ranges for continuous variables and frequencies and percentages for categorical variables. Univariable analysis was performed using the χ 2 and Fisher exact tests (if expected cell counts were less than 5) for categorical study variables, and Student t tests and Wilcoxon ranksum tests were used for continuous variables. Kaplan-Meier analysis was used to calculate the long-term risk of surgical resection to treat ICA strictures. The multivariable Cox proportional hazards model using backward variable selection (ie, step-down method) was used to identify risk factors identifiable at the time of the initial EBD associated with the requirement of surgery adjusting for confounding factors. A number of different combinations among the examined variables were tested for possible interactions, in particular among the independent factors associated with the need for salvage surgery in the final multivariable model. Restricted cubic splines were used for continuous variables to take care of possible nonlinearity of continuous predictors. The nonlinearity terms were removed from the model when shown to be unnecessary. Differences were considered to be statistically significant when a p value was <0.05 (2-sided). A nomogram was then constructed to predict the requirement of surgery. A calibration curve was generated by plotting the actual occurrence of surgical resection to treat ICA strictures against the predicted occurrence probabilities for patients to assess the prediction accuracy of the nomogram. The nomogram was built with the step-down method, where all of the variables were included at first and then nonpredictive variables or weak predictors were removed to improve the predictive performance (concordance index). The final model has the highest concordance index. The model was validated internally by a bootstrap resampling of 1000 repetitions. All of the analyses were performed using R version (R Foundation for Statistical Computing, Vienna, Austria) with survival and rms packages and SAS 9.3 software (SAS Institute, Cary, NC). RESULTS Patient Characteristics A total of 185 patients were included. The mean age was 43.1 ± 13.2 years, 45.9% were women, and 168 patients (90.8%) were white. The duration of CD was 17.6 ± 10.7 years. The mean interval from the last bowel resection was 9.9 ± 8.5 years (range, years). There were 117 patients (63.2%) who had only 1 previous surgical procedure, whereas 42 (22.7%) had 2, 12 (6.5%) had 3, and 14 (7.6%) had more than 3. Because of the high prevalence of patients undergoing index surgery elsewhere, we had available data on whether the anastomosis was performed using a handsewn or stapled technique for only 21 patients. We therefore could not include this specific variable in our analysis. At the time of EBD, 148 patients (80%) were symptomatic. Medications used at the time of EBD included 5-aminosalicylic acid (n = 19; 10.3%), immunomodulators (n = 45; 24.3%), steroids (n = 36; 19.5%), and biologics (n = 32; 17.3%). Endoscopic Balloon Dilation-Related Variables A total of 462 dilations of ICA were performed. The number of EBDs was 1 in 77 patients (41.6%), 2 in 43 (23.2%), and 3 or more in 65 (35.1%). A total of 108 patients (58.8%) had more than 1 dilation performed. The median number of per-patient dilations was 2 (range, 1 14). The median balloon size used on the initial dilation was 16.5 mm (range, 8 20 mm). The technical failure rate was 9.2% (17/185 patients), and the perforation rate was 1.1% per dilation and 2.7% per patient. Technical failure did not inevitably result in a decision for surgery, depending on the individual clinical circumstances. There were no episodes of bleeding requiring transfusion or deaths associated with EBD. Outcomes After Endoscopic Balloon Dilation During the overall mean follow-up of 3.9 ± 2.9 years, 6 patients (3.3%) developed enteric fistulas or abdominopelvic abscesses, and 66 patients (35.7%) underwent salvage surgery because of failure of nonoperative management. Twenty-seven patients (14.6%) required emergency department evaluation leading to hospitalization for stricture-related conditions, of whom 13 subsequently required salvage surgery. There was not any statistically significant association between hospital admission during follow-up after EBD and need for salvage surgery (p = 0.12). The number of patients requiring escalation of medical treatment after EBD was not significantly associated with the requirement for salvage surgery (21/66 [31.8%] vs 34/119 [28.6%]; p = 0.38). The mean follow-up among the remaining 64.3% of patients who did not undergo surgery for ICA stricture was 3.6 ± 2.9 years. The mean follow up of the 47 patients who had 1 dilation and did not require
4 426 Lian et al: Crohn s Anastomotic Stricture Dilation surgery was 1.8 years (range, years). The patient treatment algorithm is shown in Figure 1. Kaplan-Meier analysis showed that the 1-, 3-, and 5-year risks of surgery for ICA stricture after EBD were 20.8%, 33.6%, and 45.3%. There were 37 patients with a full 5- year follow-up (Fig. 2). Association Between Clinical Features and Risk of Subsequent Surgery After Endoscopic Balloon Dilation Risk factors significantly associated with the requirement of surgery on univariate analysis were more than 1 previous surgical procedure (p = 0.006), technical failure of EBD (p = 0.023), presence of concurrent bowel stricture (p = 0.008), and radiographic proximal bowel dilation (p = 0.005). The association between symptomatic rather than incidental ICA stricture and the need for salvage surgery was marginally significant (p = 0.049). Medication use before EBD, endoscopic signs of inflammation at the anastomosis (Rutgeerts score >0) on initial EBD, technique used in the construction of the ICA, and endoscopic steroid injection had no relationship with the risk of having surgery (Table 1). Subgroup Analysis of Patients With Available Imaging Data Radiographic examination within 3 months before initial EBD was performed in 129 patients, including CT (n = 98), magnetic resonance (n = 12), small-bowel series (n = 16), and abdominal plain film (n = 3). The evaluation of possible associations between radiographic features and the need for subsequent surgery is also included in Table 1. In a subgroup analysis, patients with bowel dilation proximal to ICA stricture and concurrent bowel stricture elsewhere had a significantly increased risk of requiring salvage surgery. Multivariable Cox Regression Model for Risk of Subsequent Surgery and Development of a Nomogram A Cox regression model was performed to assess the risk factor for subsequent surgery (Table 2). Significant factors associated with the requirement of surgery on multivariable analysis were symptomatic disease, longer interval from last surgery, and presence of proximal bowel dilation on an imaging study. We tested for interactions among all 4 of the predictors in the final model: proximal bowel dilation, symptomatic disease, duration of disease, and duration since last surgery. None of them was significant. A nomogram was developed to predict the 5-year surgery-free probability in patients undergoing EBD based on the above Cox regression model (Fig. 3). The predictions from the nomogram seemed to be accurate and discriminating, with a concordance index of 0.67, which was at its highest level when keeping all 4 of the variables reported in Table 2, including the nonsignificant variable of decreased duration of disease. The calibration curve showed that the prediction from our nomogram approximates the actual outcome. The nomogram was used by first locating the position on each predictor variable scale according to the predictor values. Each scale position had corresponding prognostic points (top axis). Point values for all of the predictor variables were determined consecutively and summed to arrive at a total point value. This value was then CD patients with ICA stricture (N = 185) One dilation (N = 77) Repeated dilations (N = 108) Mean number of dilations: 3.6 Surgery (N = 30, 40.0%) No surgery (N = 47) Surgery (N = 36, 33.3%) No surgery (N = 72) Mean surgery-free interval: 0.7 Mean follow-up: 1.8 Mean surgery-free interval: 2.5 Mean follow-up 4.7 Indication for surgery EBD failure (n = 22) EBD failure (n = 25) Fistula/abscess (N = 6) Fistula/abscess (n = 5) EBD perforation (N = 2) EBD perforation (n = 3) Cancer (n = 1) Severe inflammation refractory to medical therapy (n = 2) Figure 1. Outcomes after endoscopic through-the-scope balloon dilation (EBD) of ileocolic anastomosis (ICA) stricture attributed to recurrent Crohn s disease (CD).
5 Diseases of the Colon & Rectum Volume 58: 4 (2015) 427 Estimated probability of surgery, % Time, years Figure 2. Probability of surgery after endoscopic balloon dilation. located on the total point axis, from which a straight line was drawn down to determine the 5-year surgery-free probability. DISCUSSION Our study aimed at identifying factors associated with the need for surgery after initial EBD for recurrent CD at a previously fashioned ICA to understand in which patients EBD had a potential for long-term success as opposed to earlier surgery. Our data confirm safety and feasibility of EBD for recurrent CD at ICA, echoing our previous institutional experience inclusive of both primary and secondary stricture in patients with CD. 19 Our 1.1% per dilation perforation rate, corresponding with a 2.7% per-patient rate, favorably compares with the existing literature. 10,16 EBD remains an attractive alternative to medical treatment in the management of ICA stricture for recurrent CD, which is frequently associated with limited benefit and may help in distinguishing inflammatory from fibrostenotic strictures. 20 More importantly, our series provides novel information on risk factors associated with the need for surgery after initial EBD. We identified a longer interval from previous surgery and symptomatic disease as significant factors associated with the need for surgery, along with proximal bowel dilation in those patients for whom imaging was available. Type of anastomosis and endoscopic steroid injection were not associated with the need for subsequent surgery in our study. Reported risk factors associated with successful dilation include technical success during dilation, 10,21,22 shorter Points Duration of Crohn s disease (y) Interval from last surgery (y) Symptomatic disease 0 No Yes Proximal ileal dilation No Yes Total Points Predicted 5-year surgery-free probability Figure 3. Nomogram for the prediction of 5-year surgery-free probability among patients undergoing initial endoscopic balloon dilation. The nomogram is used by first locating the position on each predictor variable scale according to the predictor values. Each scale position has corresponding prognostic points (top axis). Point values for all of the predictor variables are determined consecutively and summed to arrive at a total point value, which is then located on the total point axis, from which a straight line is drawn down to determine the 5-year surgeryfree probability.
6 428 Lian et al: Crohn s Anastomotic Stricture Dilation Table 1. Univariable Cox proportional hazard model for risk factors associated with requirement of surgery after initial endoscopic dilation Variable Patient (n) Salvage surgery, n (%) Cox univariable HR (95% CI) Cox univariable, p Sex Women (42) Men (30) 0.76 ( ) 0.27 No. of previous operations (27) More than (50) 1.94 ( ) Extraintestinal manifestations No (36) Yes (34) 0.90 ( ) 0.74 Smoking history Current smoker (40)??? Former smoker (39) 0.65 ( ) 0.24 Never smoker (33) 0.60 ( ) 0.11 Passive smoker 4 1 (25) 0.53 ( ) 0.54 Symptomatic disease No (27) Yes (38) ( ) Medication use at time of EBD No (34) Anti-inflammatory agents 19 5 (26) 0.84 ( ) 0.73 Biologics 32 8 (25) 0.90 ( ) 0.80 Immunomodulators (42) 1.37 ( ) 0.34 Steroids (44) 1.57 ( ) 0.19 Anastomotic technique End-to-end 21 5 (24)??? End-to-side (24) 1.17 ( ) 0.77 Side-to-side 28 9 (32) 1.84 ( ) 0.30 Sedation General anesthesia 23 8 (35) Sedation (36) 0.67 ( ) 0.29 Age, years (36) ( ) 0.41 Duration of Crohn s disease, years (36) 0.99 ( ) 0.61 Disease duration since latest operation, years (36) ( ) 0.27 Endoscopic balloon size, mm (36) 0.97 ( ) 0.35 Rutgeerts score (31) (43) 1.20 ( ) Endoscopic steroid injection No (35) 0.52 Yes (37) 0.82 ( ) Endoscopic technical success After endoscopic dilation (34) Before endoscopic dilation 12 3 (25) 1.03 ( ) 0.96 Technical failure (59) 2.51 ( ) Concurrent radiographic bowel stricture No (32) Yes (58) 2.20 ( ) Radiographic proximal bowel dilation No (36) Yes (62) 2.12 ( ) Radiographic bowel thickening No 24 8 (33) 0.47 Yes (47) 1.32 ( ) Radiographic mucosal enhancement No (39) 0.93 Yes (46) 1.03 ( ) Data were not available for all of the subjects. Balloon size was available for 180 patients, data on anastomotic technique on 95, data on radiographic bowel thickening on 120, and data on radiographic mucosal enhancement on 120. EBD = endoscopic balloon dilation.
7 Diseases of the Colon & Rectum Volume 58: 4 (2015) 429 Table 2. Multivariable Cox proportional hazard model for risk factors associated with requirement of surgery after initial endoscopic dilation Variable Patient (n) Salvage surgery, n (%) Cox multivariable HR (95% CI) Cox multivariable, p Radiographic proximal bowel dilation No (36) Yes (62) 2.36 ( ) Symptomatic disease No 21 5 (24) Yes (48) 3.54 ( ) Decreased duration of Crohn s disease (44) 1.03 ( ) 0.12 Increased Crohn s disease duration since latest operation (44) 1.05 ( ) length of stricture, 10,17 nonulcerated stricture, 18 and duration of CD. 23 Some series have found that smoking was associated with the requirement of surgery. 18 However, the data on smoking as an adverse prognosticator after EBD are controversial. 18,24,25 Similarly, an increased C-reactive protein level has been inconsistently identified as a predictor for the need for intervention after index EBD. 16,23 In addition, some series 16 did not report any specific factor significantly associated with the need for new interventions after the index EBD, including medical therapy or active disease at the time of dilation. Our data did not include a C-reactive protein, which is not routinely used in our institution and has levels that can significantly fluctuate throughout the disease treatment. However, examination of a number of surgical and radiologic variables that have not been considered previously were included in this study, and we intentionally focused only on EBD for stricture at the ICA. We excluded, unlike most other studies, 10,16,18 both de novo CD strictures and other disease locations 14,26 so that sample heterogeneity could be minimized. We further constructed a nomogram using the above-mentioned variables that we believe can practically assist clinicians in counseling patients regarding their possibility of avoiding surgery for ICA stricture caused by recurrent CD. The present study and our previous study 19 did not show significant association between the need for surgery and intralesional steroid injection. The injection was not found to reduce the time to redilation after EBD of Crohn s ICA strictures; it had a trend toward a worse outcome in a previous pilot randomized, placebo-controlled trial. 27,28 Of note, earlier studies suggest that infliximab was associated with stricture development However, the direct link between the use of antitumor necrosis factor agents and stricture formation has been questioned. 12,32 34 The assessment of pre-ebd imaging in the present study revealed that, in those who did have imaging data, a proximal bowel dilation was associated with a higher risk of subsequent surgery. In this regard, it is however important to point out that there might be a selection bias toward patients with more severe disease undergoing imaging evaluation which, unlike colonoscopy, is not a routine follow-up study among patients who underwent ICA for CD. The other limitations of our study are related to its retrospective design. For example, the degree and the precise length of strictures could not be quantified in this study, and heterogeneity of patients characteristics remains inevitable. In particular, the clinical decision making on whether EBD or surgery was indicated for each individual patient was subjective and dependent on a variety of specific clinical circumstances. Future studies will be needed to assess the implications on long-term disease activity, quality of life, and reoperation rates of EBD when compared with upfront surgery for recurrent ICA stricture, which arguably might allow for a longer intervention-free survival by resecting rather than manipulating the anastomotic area of recurrence. In particular, although a subset of our patients did not require surgery for several years after EBD, we cannot reliably conclude that EBD saved them from an operation for CD without assessing a control group that was not treated with EBD for a comparable ICA stricture. CONCLUSION EBD seems to be a safe and effective treatment modality. Patients with significant risk factors adversely affecting their nomogram scores should be counseled against EBD and recommended upfront surgery to treat recurrent CD. REFERENCES 1. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn s disease: a systematic review. Inflamm Bowel Dis. 2012;18: Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn s disease in adults. Am J Gastroenterol. 2009;104: Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn s disease at the ileocolic anastomosis after curative surgery. Gut. 1984;25:
8 430 Lian et al: Crohn s Anastomotic Stricture Dilation 4. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn s disease. Gastroenterology. 1990;99: Rutgeerts P. Protagonist: Crohn s disease recurrence can be prevented after ileal resection. Gut. 2002;51: Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn s disease strictures. Inflamm Bowel Dis. 2004;10: Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilation for stricturing Crohn s disease review of the literature. Int J Colorectal Dis. 2010;25: Yamamoto T. Factors affecting recurrence after surgery for Crohn s disease. World J Gastroenterol. 2005;11: Koltun WA. Long-term value of endoscopic dilation for Crohn s strictures. Gut. 2010;59: Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilation in Crohn s disease. Aliment Pharmacol Ther. 2007;26: Rolny P. Anastomotic strictures in Crohn s disease: a new field for therapeutic endoscopy. Gastrointest Endosc. 1993;39: sorrentino D. Role of biologics and other therapies in stricturing Crohn s disease: what have we learnt so far? Digestion. 2008;77: foster EN, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. J Clin Gastroenterol. 2008;42: endo K, Takahashi S, Shiga H, Kakuta Y, Kinouchi Y, Shimosegawa T. Short and long-term outcomes of endoscopic balloon dilation for Crohn s disease strictures. World J Gastroenterol. 2013;19: nanda K, Courtney W, Keegan D, et al. Prolonged avoidance of repeat surgery with endoscopic balloon dilation of anastomotic strictures in Crohn s disease. J Crohns Colitis. 2013;7: thienpont C, D Hoore A, Vermeire S, et al. Long-term outcome of endoscopic dilation in patients with Crohn s disease is not affected by disease activity or medical therapy. Gut. 2010;59: Mueller T, Rieder B, Bechtner G, Pfeiffer A. The response of Crohn s strictures to endoscopic balloon dilation. Aliment Pharmacol Ther. 2010;31: hoffmann JC, Heller F, Faiss S, et al. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis. 2008;23: atreja A, Aggarwal A, Dwivedi S, et al. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn s disease strictures. J Crohns Colitis. 2014;8: Lenze F, Wessling J, Bremer J, et al. Detection and differentiation of inflammatory versus fibromatous Crohn s disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis. 2012;18: scimeca D, Mocciaro F, Cottone M, et al. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn s disease strictures. Dig Liver Dis. 2011;43: Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilation of ileocolic Crohn s strictures: a prospective longterm analysis. Gut. 1995;36: Bhalme M, Sarkar S, Lal S, Bodger K, Baker R, Willert RP. Endoscopic balloon dilation of Crohn s disease strictures: results from a large United Kingdom series. Inflamm Bowel Dis. 2014;20: Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003;15: Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn s disease. Aliment Pharmacol Ther. 2013;37: foster EN, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. J Clin Gastroenterol. 2008;42: Brooker JC, Beckett CG, Saunders BP, Benson MJ. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn s strictures may improve the outcome: a retrospective case series. Endoscopy. 2003;35: East JE, Brooker JC, Rutter MD, Saunders BP. A pilot study of intrastricture steroid versus placebo injection after balloon dilation of Crohn s strictures. Clin Gastroenterol Hepatol. 2007;5: D haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn s disease: a European multicenter trial. Gastroenterology. 1999;116: Vasilopoulos S, Kugathasan S, Saeian K, et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn s disease. Am J Gastroenterol. 2000;95: toy LS, Scherl EJ, Kornbluth A, et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn s disease: a series of a newly described complication. Gastroenterology. 2000;118:A lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn s disease. Am J Gastroenterol. 2006;101: Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn s disease complicated by strictures: a systematic review. Gut. 2013;62: Pallotta N, Barberani F, Hassan NA, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn s disease. World J Gastroenterol. 2008;14:
Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn s disease
Alimentary Pharmacology and Therapeutics Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn s disease A. Gustavsson*,, A. Magnuson, B. Blomberg*, M. Andersson, J.
More informationTubercular versus Crohn s ileal strictures: role of endoscopic balloon dilatation without fluoroscopy
ORIGINAL ARTICLE Annals of Gastroenterology (2013) 26, 1-5 Tubercular versus Crohn s ileal strictures: role of endoscopic balloon dilatation without fluoroscopy Surinder Singh Rana, Deepak Kumar Bhasin,
More informationSafety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease
Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal
More informationLong-Term Outcomes of Endoscopic Balloon Dilation for Benign Strictures in Patients with Inflammatory Bowel Disease
Gut and Liver, Vol. 12, No. 5, September 2018, pp. 530-536 ORiginal Article Long-Term Outcomes of Endoscopic Balloon Dilation for Benign Strictures in Patients with Inflammatory Bowel Disease Hye Won Lee
More informationSystematic review with meta-analysis: endoscopic balloon dilatation for Crohn s disease strictures
Alimentary Pharmacology and Therapeutics Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn s disease strictures P. S. Morar*,, O. Faiz*,, J. Warusavitarne*,, S. Brown, R. Cohen,
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationEndoscopic Balloon Dilation for Crohn s Disease-Associated Strictures
FOCUSED REVIEW SERIES: Current Status of Endoscopy in the Management of Inflammatory Bowel Disease Clin Endosc 2017;50:429-436 https://doi.org/10.5946/ce.2017.147 Print ISSN 2234-2400 On-line ISSN 2234-2443
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon http://journal-arc.jp ORIGINAL RESEARCH ARTICLE Risk factors for recurrence of Crohn s disease requiring surgery in patients receiving post-operative anti-tumor necrosis
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationCrohn s Disease: A New Approach to an Old Problem
Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationFindings of Retrograde Contrast Study Through Double-balloon. Enteroscopy Predict the Risk of Bowel Resections in Patients with
Okazaki et al. 1 Findings of Retrograde Contrast Study Through Double-balloon Enteroscopy Predict the Risk of Bowel Resections in Patients with Crohn s Disease with Small Bowel Stenosis Noriko Okazaki*,
More informationImpact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence
1130-0108/2015/107/10/586-590 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 10, pp. 586-590, 2015 ORIGINAL PAPERS Impact of endoscopic
More informationThis is a repository copy of Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures..
This is a repository copy of Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk//
More informationThe role of endoscopy in inflammatory bowel disease
European Review for Medical and Pharmacological Sciences The role of endoscopy in inflammatory bowel disease M. DAPERNO, R. SOSTEGNI, A. LAVAGNA, L. CROCELLÀ, E. ERCOLE, C. RIGAZIO, R. ROCCA, A. PERA Center
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationT he treatment strategy for Crohn s disease (CD) is
237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P
More informationDoes Anastomosis Configuration Influence Long-term Outcomes in Patients With Crohn Disease?
Original Article Ann Coloproctol 217;33(5):173-177 https://doi.org/1.3393/ac.217.33.5.173 pissn 2287-9714 eissn 2287-9722 Does Anastomosis Configuration Influence Long-term Outcomes in Patients With Crohn
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationHomayoon Akbari, MD, PhD
Recent Advances in IBD Surgery Homayoon M. Akbari, MD, PhD, FRCS(C), FACS Associate Professor of Surgery Virginia Commonwealth University Crohn s disease first described as a surgical condition, with the
More informationPrevention and Management of Postoperative Crohn s disease
Prevention and Management of Postoperative Crohn s disease Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center Director, Gastroenterology,
More informationDifferentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics
38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya
More informationThe Use of Ultrasound in the Diagnosis of Crohn's Disease
American Academy of Pediatrics CA2 Ashley Wachsman, MD Namita Singh, MD Newsletter June 2016 Cindy E. Kallman, MD The Use of Ultrasound in the Diagnosis of Crohn's Disease A few years ago, a prominent
More informationClinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152
Crohn's disease: management Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationEndoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.
F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann@em.uni-frankfurt.de Indications for endoscopy Diagnosis Management Surveillance Diagnosis Single most valuable tool: ileocolonoscopy
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationFibrotic complications of inflammatory bowel disease
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fibrotic complications of inflammatory bowel disease Gerhard Rogler, Department of Gastroenterology
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationPreventing post-operative recurrence
Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting Talk Outline Risk factors for
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationComparison of Diagnostic Accuracy and Impact of Magnetic Resonance Imaging and Colonoscopy for the Management of Crohn s Disease
Journal of Crohn's and Colitis, 2016, 663 669 doi:10.1093/ecco-jcc/jjw015 Advance Access publication January 18, 2016 Original Article Original Article Comparison of Diagnostic Accuracy and Impact of Magnetic
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationPresence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos
More informationIleal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
More informationI nflammatory bowel diseases (IBD) are chronic intestinal
364 INFLAMMATORY BOWEL DISEASE Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn s disease F Costa, M G Mumolo, L Ceccarelli, M Bellini, M R Romano, C Sterpi,
More informationInflammatory Bowel Disease and Surgery: What You Should Know
Inflammatory Bowel Disease and Surgery: What You Should Know Ask the Experts March 9, 2019 Kristen Blaker, MD Colon and Rectal Surgery MetroHealth Medical Center Disclosures None Outline Who undergoes
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationDiagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease
Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease Lena B. Palmer MD, Carol Q. Porter, Michael D. Kappelman MD MPH No relevant financial disclosures
More informationSurgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?
17 th Panhellenic IBD Congress Thessaloniki May 2018 Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma? Janindra Warusavitarne Consultant Colorectal Surgeon, St
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationPredictors of recurrence of Crohn s disease after ileocolectomy: A review
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i39.14393 World J Gastroenterol 2014 October 21; 20(39): 14393-14406 ISSN 1007-9327
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationSurgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationUNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA"
UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA" FACOLTA' DI MEDICINA e CHIRUGIA DOTTORATO DI RICERCA IN FISIOPATOLOGIA SPERIMENTALE CICLO DEL CORSO DI DOTTORATO XXII Postoperative Crohn's Disease recurrence
More informationDepartment of Medicine 1, University of Erlangen-Nuremberg, Ulmenweg 18, D Erlangen, Germany; 2
Int J Clin Exp Pathol 2014;7(11):7419-7431 www.ijcep.com /ISSN:1936-2625/IJCEP0003628 Original Article Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel
More informationSurgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationExpert Forum IBD Ahead 2011: National Meeting
Expert Forum IBD Ahead 2011: National Meeting Making Education Easy 5 th Annual Exchange on Advances in IBD July 2011 Attendees Dr Malcolm Arnold Professor Gil Barbezat Professor Murray Barclay Dr Nicholas
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationCASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD
CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant
More informationCrohn disease is a chronic inflammatory bowel disease
GASTROENTEROLOGY 2010;139:1147 1155 Risk Factors Associated With Progression to Intestinal Complications of Crohn s Disease in a Population-Based Cohort KELVIN T. THIA,*, WILLIAM J. SANDBORN,* WILLIAM
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationPredictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease
Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease Jason Etzel Resident Research Forum Seattle VAMC 6/13/08 Background Increased
More informationEffectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
Dig Dis Sci (2013) 58:1329 1334 DOI 10.1007/s10620-012-2374-2 ORIGINAL ARTICLE Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
More informationApproximately 80% of patients with Crohn s disease
CLINICAL REVIEW Postoperative Recurrent Luminal Crohn s Disease: A Systematic Review Peter De Cruz, MD, Michael A. Kamm, PhD, Lani Prideaux, MD, Patrick B. Allen, MD, and Paul V. Desmond, MD Abstract:
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University.
Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Chronic transmural inflammatory process of the bowel & affects any part of the gastro -intestinal tract from the mouth to the
More informationDeep Enteroscopy Methods to Diagnose Small Bowel IBD
Deep Enteroscopy Methods to Diagnose Small Bowel IBD Name: Institution: Peter Draganov University of Florida, Gainesville, FL Overview Types of enteroscopy Enteroscopy equipment Enetoscopy do and don'ts
More informationIncidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:760 765 Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis DAVID N. MOSKOVITZ, GERT VAN
More informationEuropean evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management
European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management J. Martin-Comin Hospital U. Bellvitge Hospitalet de Llobregat Spain THE EUROPEAN
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationBut.. Capsule Endoscopy. Guidelines (OMED ECCO) Why is Enteroscopy so Important? 4/19/2017
Dr. Elizabeth Odstrcil Digestive Health Associates of Texas April 22, 2017 But.. Capsules fail to reach the cecum in as many as 25% of patients Patients with known CD have a risk of capsule retention of
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationSURGICAL MANAGEMENT OF ULCERATIVE COLITIS
SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationSMALL BOWEL ADENOCARCINOMA. Dr. C. Jeske
SMALL BOWEL ADENOCARCINOMA Dr. C. Jeske Case presentation 54 year old female. Presents with OJ and weight loss. Abdominal examination only reveals a palpable gallbladder. ERCP reveals a circumferential
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationIleo-rectal anastomosis for Crohn's disease of
Ileo-rectal anastomosis for Crohn's disease of the colon W. N. W. BAKER From the Research Department, St Mark's Hospital, London Gut, 1971, 12, 427-431 SUMMARY Twenty-six cases of Crohn's disease of the
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationGuided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology
More informationDiagnostic techniques for surveillance of dysplasia
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Diagnostic techniques for surveillance of dysplasia Gerhard Rogler, Department of Gastroenterology
More informationJonathan R. Dillman, MD, MSc. Associate Professor Department of Radiology Cincinnati Children s Hospital Medical Center
MR Enterography in Children: Interpretation & Value-Added Jonathan R. Dillman, MD, MSc Associate Professor Department of Radiology Cincinnati Children s Hospital Medical Center Disclosures Crohn s disease
More informationCigdem Benlice, Ipek Sapci, T. Bora Cengiz, Luca Stocchi, Michael Valente, Tracy Hull, Scott R. Steele, Emre Gorgun 07/23/2018
Does preoperative oral antibiotic or mechanical bowel preparation increase Clostridium difficile colitis after colon surgery? An assessment from ACS-NSQIP procedure-targeted database Cigdem Benlice, Ipek
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More informationchildren Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae
MR enterography for Crohn s disease in children BOAZ KARMAZYN, MD PEDIATRIC RADIOLOGY ASSOCIATE PROFESSOR Characterization Crohn disease Idiopathic chronic transmural IBD Increasing incidence Age 7/100,000
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationThe medical management of Crohn s disease remains a
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:679 683 Computed Tomography Enterography Detects Intestinal Wall Changes and Effects of Treatment in Patients With Crohn s Disease DAVID H. BRUINING,* EDWARD
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationGRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM
GASTROENTEROLOGY 64: 1071-1076, 1973 Copyright 1973 by The Williams & Wilkins Co. Vol. 64, No.6 Printed in U.S.A. GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM JAMES A. NELSON,
More informationInfliximab Therapy in Pediatric Patients 7 Years of Age and Younger
ORIGINAL ARTICLE: GASTROENTEROLOGY Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger Judith R. Kelsen, Andrew B. Grossman, Helen Pauly-Hubbard, Kernika Gupta, Robert N. Baldassano, and
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More information